grepcent public filings, reorganized for comparison

RINVOQ LQ — FDA application NDA218347

Application NDA218347 · type NDA · FDA status: approved · original approval 2024-04-26

Listed sponsor: ABBVIE · ABBV company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

ProductFDA-listed trade nameActive ingredientDosage formRouteStrengthMarketing statusTE codeRLD
001RINVOQ LQUPADACITINIBSOLUTIONORAL1MG/MLPrescriptionnot listedYes

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Orange Book patent and exclusivity listings

ListingProductDescriptive dateFlags/code
Patent 8962629001listed patent expiry date: 2031-01-15drug substance, U-3946
Patent 8962629001listed patent expiry date: 2031-01-15drug substance, U-3945
Patent RE47221001listed patent expiry date: 2033-08-16drug substance
Patent 10981923001listed patent expiry date: 2036-10-17drug substance
Patent 11186584001listed patent expiry date: 2036-10-17drug substance
Patent 11661425001listed patent expiry date: 2036-10-17drug substance
Patent 11680069001listed patent expiry date: 2036-10-17drug substance
Patent 11718627001listed patent expiry date: 2036-10-17drug substance
Patent 11773105001listed patent expiry date: 2036-10-17drug substance
Patent 12110298001listed patent expiry date: 2036-10-17drug substance
Patent 12365689001listed patent expiry date: 2036-10-17U-3945
Patent 9951080001listed patent expiry date: 2036-10-17drug substance
Exclusivity NP001listed exclusivity date: 2027-04-26FDA code as listed
Exclusivity ODE-481001listed exclusivity date: 2031-04-26FDA code as listed
NDA218347 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA218347 FDA listing dates. Source: Drugs@FDA and FDA Orange Book.NDA218347 FDA listing datesDescriptive regulatory dates only; no relationship to revenue or future sales is stated or implied.Source: Drugs@FDA and FDA Orange Book.Listed dateDated listing marker0.001.002.002024-04-261.002027-04-261.002031-01-151.002031-04-261.002033-08-161.002036-10-171.00

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

Compound cross-links

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Related pages

Sponsor company · FDA-approved application index

Peer clusters: Large-cap biopharma

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.